NKGN: מקדם מחיר להכנסות NKGen

Geopolitical risks are disrupting supply chains, yet potential monopoly pricing in Alzheimer's treatment creates high value. The market capitalization-to-revenue ratio confirms these fluctuations, where shows the level of this metric. The innovative cell therapy of NKGen Biotech, Inc. (NKGN) promises stable income due to the chronic nature of the disease and long-term patent protection.

When constructing a long-term portfolio, fundamental screening requires assessing an asset's market value relative to its ability to generate cash flow. The P/S ratio compares market capitalization to annual sales volume, which is critical for NKGen Biotech, Inc. (NKGN), as its unique cell therapy for Alzheimer's disease establishes a foundation for long-term patent revenues, reflecting investment potential through the P/S ratio chart.